Molecular markers in prostate cancer. Part I: predicting lethality

Area of Science:

• Urology
• Oncology
• Molecular Pathology

Background:

• Distinguishing lethal early prostate cancer (PCa) from indolent disease remains a clinical challenge.
• Active surveillance is an alternative to radical treatment for many men, but judicious intervention is difficult to judge.
• Clinical factors alone are insufficient for accurate prognostication.

Purpose of the Study:

• To review molecular markers and models for predicting PCa stage, progression, and lethality.
• To provide an overview of advancements up to 2008 in identifying clinically valuable biomarkers.
• To aid clinicians in balancing intervention versus overtreatment for early PCa.

Main Methods:

• Literature review of studies published up to and including 2008.
• Synthesis of findings on molecular markers and predictive models for prostate cancer.
• Analysis of the clinical utility of various biomarkers.

Main Results:

• Many molecular markers have been investigated for predicting PCa outcomes.
• Few individual markers demonstrate sufficient clinical value alone.
• Molecular markers are often most useful within multivariate predictive models.

Conclusions:

• Accurate assessment of early prostate cancer lethality is crucial for appropriate management.
• Molecular markers, when integrated into models, can enhance prognostic accuracy.
• Further research is needed to refine predictive tools for personalized PCa treatment.